Can I read Adjuvant Therapy for High-risk Primary and Resected Metastatic Melanoma on EtoBox?

Adjuvant Therapy for High-risk Primary and Resected Metastatic Melanoma by P. Hersey is a Medicine article available to read on EtoBox.

What is Adjuvant Therapy for High-risk Primary and Resected Metastatic Melanoma about?

**Abstract** Patients with thick, primary melanoma and regional lymph‐node metastases are at moderate to high risk of recurrence and death, despite apparent complete surgical removal. Immune responses can be demonstrated against melanoma and this has prompted the conduct of a number of randomized trials of immunotherapy. Several trials have been completed and show minimal benefit in prolonging survival or recurrence from melanoma. Similarly, a large number of trials has been conducted to test the efficacy of α‐2‐interferon (IFN‐α2) in therapy. Clear benefit in recurrence‐free survival was shown in several trials, however there is a lack of convincing evidence of an effect on overall survival. Several trials of vaccine and IFN‐α2 therapy are still in progress and their results are awaited with great interest. The use of high‐dose IFN‐α2 therapy remains a contentious subject, however available evidence suggests the standard of care remains good surgical management. (Intern Med J 2003; 33: 31−41)

Who reads Adjuvant Therapy for High-risk Primary and Resected Metastatic Melanoma?

Author

P. Hersey

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 1444-0903)

Published

2003

Language

EN

Field

Medicine (Health Sciences)